LAVAL, Quebec, Nov. 25, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Dr. Ari Kellen has been named to Valeant’s Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1, 2014.
Dr. Ari Kellen was a senior partner in McKinsey & Company’s Mid-Atlantic Office. Since joining McKinsey in March 1991, Ari has led numerous strategy, organization and performance improvement studies for health care companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharmaceutical and biotechnology, and health care services clients, and regional and country growth strategies. In addition, Ari developed business model innovation and turnaround strategies as well as top level organization structure, governance and decision-making redesigns. Ari directed performance turnarounds addressing revenue, cost, capital and change management. Ari received a Bachelor of Medicine and Bachelor of Surgery (MBBCh) degree and an MBA degree, both with distinction, from the University of the Witwatersrand in South Africa.
“The Board of Directors and I are pleased to include Ari as another strong addition to Valeant’s senior management team,” said J. Michael Pearson, chairman and chief executive officer. “Ari’s broad experience in developing comprehensive growth strategies for health care companies will be invaluable to us as we continue to expand our successful growth trends. After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant.”
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
This press release may contain forward-looking statements. These forward-looking statements relate to, among other things, the opportunities that lie ahead and the future roles of certain management. Forward-looking statements can generally be identified by the use of words such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “continue,” “plan,” “project,” “will,” “may,” “should,” “could,” “would,” “target,” “potential,” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things, the ability of Valeant to capitalize on opportunities, the changing roles of management and the risk factors as detailed from time to time in Valeant’s reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release.
SOURCE Valeant Pharmaceuticals International, Inc.